✦ LIBER ✦

Diabetes mellitus and prostate cancer risk in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial

✍ Scribed by Michael F. Leitzmann; Jiyoung Ahn; Demetrius Albanes; Ann W. Hsing; Arthur Schatzkin; Shih-Chen Chang; Wen-Yi Huang; Jocelyn M. Weiss; Kim N. Danforth; Robert L. Grubb; Gerald L. Andriole; for the Prostate, Lung, Colorectal, and Ovarian (PLCO) Trial Project Team

Publisher: Springer Netherlands
Year: 2008
Tongue: English
Weight: 246 KB
Volume: 19
Category: Article
ISSN: 0957-5243
DOI: 10.1007/s10552-008-9198-6

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

The prostate, lung, colorectal, and ovar

The prostate, lung, colorectal, and ovarian cancer screening trial of the national cancer institute

✍ John K. Gohagan; Philip C. Prorok; Barnett S. Kramer; Richard B. Hayes; Joyce E. 📂 Article 📅 1995 🏛 John Wiley and Sons 🌐 English ⚖ 481 KB 👁 2 views

The two-year pilot phase of the Prostate, Lung, Colorectal, and Ovarian (PLCO) trial concluded September 29, 1994. The goals, organization, operation, and recruitment status of the trial are discussed. The PLCO trial is a 16year randomized controlled screening trial involving 148,000 male and female

IGF-1 and IGFBP-3: Risk of prostate canc

IGF-1 and IGFBP-3: Risk of prostate cancer among men in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial

✍ Jocelyn M. Weiss; Wen-Yi Huang; Sabina Rinaldi; Thomas R. Fears; Nilanjan Chatte 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 French ⚖ 91 KB 👁 1 views

## Abstract IGF‐1 and IGFBP‐3 may influence risk of prostate cancer through their roles in cellular growth, metabolism and apoptosis, however, epidemiologic results have been inconsistent. The role of obesity in prostate cancer risk is not clearly understood, but hyperinsulinemia‐related increases

A national cancer institute sponsored sc

A national cancer institute sponsored screening trial for prostatic, lung, colorectal, and ovarian cancers

✍ Barnett S. Kramer; John Gohagan; Philip C. Prorok; Charles Smart 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 522 KB

Background. Ovarian cancer is the fifth most common cause of cancer-related death in American women. The median age at diagnosis is about 62 years; incidence rises rapidly after age 60. Pelvic examination has been the primary method for detection of ovarian carcinoma. It is insensitive for the detec

Dietary carbohydrate, glycemic index, gl

Dietary carbohydrate, glycemic index, glycemic load, and risk of prostate cancer in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial (PLCO) cohort

✍ James M. Shikany; Andrew P. Flood; Cari M. Kitahara; Ann W. Hsing; Tamra E. Meye 📂 Article 📅 2011 🏛 Springer Netherlands 🌐 English ⚖ 217 KB

Large-scale randomized prostate cancer s

Large-scale randomized prostate cancer screening trials: Program performances in the European randomized screening for prostate cancer trial and the prostate, lung, colorectal and ovary cancer trial

✍ Harry J. de Koning; Anssi Auvinen; Antonio Berenguer Sanchez; Fernando Calais da 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 French ⚖ 79 KB 👁 2 views

## Abstract Two large‐scale randomized screening trials, the Prostate, Lung, Colorectal and Ovary (PLCO) cancer trial in the USA and the European Randomized Screening for Prostate Cancer (ERSPC) trial in Europe are currently under way, aimed at assessing whether screening reduces prostate cancer mo

Image Quality Assurance in the Prostate,

Image Quality Assurance in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial Network of the National Lung Screening Trial

✍ Stephen M. Moore; David S. Gierada; Kenneth W. Clark; G. James Blaine 📂 Article 📅 2005 🏛 Springer-Verlag 🌐 English ⚖ 768 KB